XML 222 R140.htm IDEA: XBRL DOCUMENT
v3.22.4

Collaborative and Other Relationships - Other Arrangements (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 1 Months Ended | 12 Months Ended |
--- | --- | --- | ---
Aug. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Apr. 30, 2020 | Feb. 29, 2020 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2023
Collaborative arrangements and non-collaborative arrangement transactions |  |  |  |  |  |  |  |  |
Potential future milestone payments commitment to third party approximately |  |  |  |  |  | $ 9,300.0 |  |  |
Research and development |  |  |  |  |  | 2,231.1 | $ 2,501.2 | $ 3,990.9 |
Sage Therapeutics |  |  |  |  |  |  |  |  |
Collaborative arrangements and non-collaborative arrangement transactions |  |  |  |  |  |  |  |  |
Global licensing collaboration, shares purchased, amount |  | $ 650.0 |  |  |  |  |  |  |
Global licensing collaboration, shares purchased (in shares) |  | 6.2 |  |  |  |  |  |  |
Global licensing collaboration, purchase price per share (in dollars per share) |  | $ 104.14 |  |  |  |  |  |  |
Research and development expense asset acquired |  | $ 209.0 |  |  |  |  |  |  |
Upfront and milestone payments made to collaborative partner |  | 875.0 |  |  |  |  |  |  |
Global licensing collaboration, development and commercial milestone payments |  | $ 1,600.0 |  |  |  |  |  |  |
Sage Therapeutics | Forecast |  |  |  |  |  |  |  |  |
Collaborative arrangements and non-collaborative arrangement transactions |  |  |  |  |  |  |  |  |
Potential future milestone payments commitment to third party approximately |  |  |  |  |  |  |  |  | $ 225.0
Denali Therapeutics |  |  |  |  |  |  |  |  |
Collaborative arrangements and non-collaborative arrangement transactions |  |  |  |  |  |  |  |  |
Global licensing collaboration, shares purchased, amount |  |  | $ 465.0 |  |  |  |  |  |
Global licensing collaboration, shares purchased (in shares) |  |  | 13.0 |  |  |  |  |  |
Global licensing collaboration, purchase price per share (in dollars per share) |  |  | $ 34.94 |  |  |  |  |  |
Research and development expense asset acquired |  |  | $ 41.3 |  |  |  |  |  |
Upfront and milestone payments made to collaborative partner |  |  | 560.0 |  |  |  |  |  |
Global licensing collaboration, development and commercial milestone payments |  |  | $ 1,100.0 |  |  |  |  |  |
Sangamo Therapeutics, Inc. Agreement |  |  |  |  |  |  |  |  |
Collaborative arrangements and non-collaborative arrangement transactions |  |  |  |  |  |  |  |  |
Global licensing collaboration, shares purchased, amount |  |  |  | $ 225.0 |  |  |  |  |
Global licensing collaboration, shares purchased (in shares) |  |  |  | 24.0 |  |  |  |  |
Global licensing collaboration, purchase price per share (in dollars per share) |  |  |  | $ 9.21 |  |  |  |  |
Research and development expense asset acquired |  |  |  |  | $ 83.0 |  |  |  |
Upfront and milestone payments made to collaborative partner |  |  |  |  | 125.0 |  |  |  |
Global licensing collaboration, development and commercial milestone payments |  |  |  |  | $ 2,400.0 |  |  |  |
Term of collaboration agreement |  |  |  |  | 5 years |  |  |  |
Global licensing collaboration, payment, selection of targets |  |  |  |  | $ 80.0 |  |  |  |
Global licensing collaboration, payment, first milestone |  |  |  |  | 1,900.0 |  |  |  |
Global licensing collaboration, payment, sales based milestone |  |  |  |  | $ 380.0 |  |  |  |
Other research and discovery |  |  |  |  |  |  |  |  |
Collaborative arrangements and non-collaborative arrangement transactions |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  | $ 39.2 | $ 89.1 | $ 92.1 |
InnoCare Pharma Limited (InnoCare) Agreement |  |  |  |  |  |  |  |  |
Collaborative arrangements and non-collaborative arrangement transactions |  |  |  |  |  |  |  |  |
Upfront and milestone payments made to collaborative partner | $ 125.0 |  |  |  |  |  |  |  |
Contingent milestone payments made to collaborative partner | $ 812.5 |  |  |  |  |  |  |  |

X
- Definition Contingent Milestone Payments Made To Collaborative Partner + References No definition available. + Details
Name: | biib_ContingentMilestonePaymentsMadeToCollaborativePartner
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Global Licensing Collaboration Agreement, Amount, Shares Purchased + References No definition available. + Details
Name: | biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones + References No definition available. + Details
Name: | biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones + References No definition available. + Details
Name: | biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Global Licensing Collaboration Agreement, Payment, Selection of Targets + References No definition available. + Details
Name: | biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Global Licensing Collaboration Agreement, Purchase Price Per Share + References No definition available. + Details
Name: | biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare
Namespace Prefix: | biib_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments + References No definition available. + Details
Name: | biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Global Licensing Collaboration Agreement, Shares, Purchased + References No definition available. + Details
Name: | biib_GlobalLicensingCollaborationAgreementSharesPurchased
Namespace Prefix: | biib_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential future milestone payments commitment to third party approximately. + References No definition available. + Details
Name: | biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Term of collaboration agreement + References No definition available. + Details
Name: | biib_Termofcollaborationagreement
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total upfront and milestone payments made to collaborative partner. + References No definition available. + Details
Name: | biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsIncAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |